Immunohistochemical detection of the BRAF V600E mutation in melanoma patients with monoclonal antibody VE1

Pathology International

Volumn 64, Issue 12, 2014, Pages 601-606

  Liu, Hui ^a   Li, Zhongwu ^a   Wang, Yan ^a   Feng, Qin ^a   Si, Lu ^a   Cui, Chuanliang ^a   Guo, Jun ^a   Xue, Weicheng ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

BRAF V600E mutation; Immunohistochemistry; Melanoma

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADULT; DIAGNOSTIC USE; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY;

ADULT; ANTIBODIES, MONOCLONAL; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS B-RAF; SENSITIVITY AND SPECIFICITY; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84912574184     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/pin.12215     Document Type: Article

References (28)

1. Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med 2006; 355: 51-65.
2. Chapman PB, Hauschild A, Robert C etal. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
3. Sosman JA, Kim KB, Schucher L etal. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366: 707-714.
4. Turner DJ, Zirvi MA, Barany F etal. Detection of the BRAF V600E mutation in melanocytic lesions using the ligase detection reaction. J Cutan Pathol 2005; 32: 334-339.
5. Spittle C, Ward MR, Nathanson KL etal. Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. J Mol Diagn 2007; 9: 464-471.
6. Laud K, Kannengiesser C, Avril MF etal. BRAF as a melanoma susceptibility candidate gene? Cancer Res 2003; 63: 3061-3065.
7. Davies H, Bignell GR, Cox C etal. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
8. Capper D, Berghoff AS, Magerle M etal. Immunohistochemical testing of BRAF V600E status in 1, 120 tumor tissue samples of patients with brain metastases. Acta Neuropathol 2012; 123: 223-233.
9. Koperek O, Kornauth C, Capper D etal. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol 2012; 36: 844-850.
10. Long GV, Wilmott JS, Capper D etal. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol 2013; 37: 61-65.
11. Ilie M, Long E, Hofman V etal. Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. Ann Oncol 2013; 24: 742-748.
12. Bösmüller H, Fischer A, Pham DL etal. Detection of the BRAF V600E mutation in serous ovarian tumors: A comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR. Hum Pathol 2013; 44: 329-335.
13. Adackapara CA, Sholl LM, Barletta JA etal. Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma. Histopathology 2013; 63: 187-193.
14. Yi ES, Boland JM, Maleszewski JJ etal. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol 2011; 6: 459-465.
15. Si L, Kong Y, Xu X etal. Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur J Cancer 2012; 48: 94-100.
16. Kong Y, Si L, Zhu Y etal. Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res 2011; 17: 1684-1691.
17. Tan YH, Liu Y, Eu KW etal. Detection of BRAF V600E mutation by pyrosequencing. Pathology 2008; 40: 295-298.
18. Bollag G, Tsai J, Zhang J etal. Vemurafenib: The first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov 2012; 11: 873-886.
19. Capper D, Preusser M, Habel A etal. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 2011; 122: 11-19.
20. Colomba E, Hélias-Rodzewicz Z, Von Deimling A etal. Detection of BRAF p. V600E mutations in melanomas: Comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. J Mol Diagn 2013; 15: 94-100.
21. Boursault L, Haddad V, Vergier B etal. Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing. PLoS ONE 2013; 8: e70826.
22. Routhier CA, Mochel MC, Lynch K etal. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas. Hum Pathol 2013; 44: 2563-2570.
23. Busam KJ, Hedvat C, Pulitzer M etal. Immunohistochemical analysis of BRAFV600E expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions. Am J Surg Pathol 2013; 37: 413-420.
24. Yancovitz M, Litterman A, Yoon J etal. Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma. PLoS ONE 2012; 7: e29336.
25. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013; 501: 338-345.
26. Pollock PM, Harper UL, Hansen KS etal. High frequency of BRAF mutations in nevi. Nat Genet 2003; 33: 19-20.
27. Kumar R, Angelini S, Snellman E etal. BRAF mutations are common somatic events in melanocytic nevi. J Invest Dermatol 2004; 122: 342-348.
28. Poynter JN, Elder JT, Fullen DR etal. BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res 2006; 16: 267-273.